Stevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream
Keywords:
Imiquimod, Stevens-Johnson Syndrome, Erythema multiforme, Adverse Drug ReactionsAbstract
Introduction: Topical imiquimod is a safe and effective treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. The treatment is commonly associated with local inflammatory reactions, while systemic side effects are rare and generally mild. Only few cases of erythema multiforme and Stevens-Johnson syndrome have been described in association with topical imiquimod application.
Objective: We present a review of the existing cases of erythema multiforme and Stevens-Johnson syndrome reported in the literature, analyzing the clinical appearance, the histology and the treatment of the lesions.
Method: Nine case of erythema multiforme were reported, characterized by cutaneous rash, bullae, crusting, erosive and targetoid lesions, mainly located at the extremities. Mucosal involvement and systemic symptoms were sometimes present.
Results: Three cases of Stevens-Johnson syndrome were associated with topical imiquimod. In all cases, the authors reported targetoid lesions and areas of erosion affecting trunk and limbs, associated with systemic symptoms, and, in 2 cases, to mucosal erosions.
Conclusions: We hypothesize a possible role of interferon-γ, a cytokine involved in the pathogenesis of both herpes-associated erythema multiforme and Stevens-Johnson syndrome, which is released in response to the administration of imiquimod.
References
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May;50(5):722-33. DOI: 10.1016/j.jaad.2003.11.066. PMID: 15097956.
Nanda J, Bermudez R. Imiquimod. 2022 Jul 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Camacho Molina A, Alarcón Manoja E, Corzo Gilabert JR, García Gil D. Erythema multiforme induced by topical imiquimod. Emergencias. 2020;32:219.
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Erythema Multiforme. Clin Rev Allergy Immunol. 2018;54:177-184.
Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. J Dtsch Dermatol Ges. 2020 Jun;18(6):547-553. DOI: 10.1111/ddg.14118. Epub 2020 May 29. PMID: 32469468.)
García-Arpa M, Rodríguez-Vázquez M, Delgado Portela M, Vera Iglesias E. Eritema multiforme por imiquimod 5% crema [Erythema multiforme due to 5% imiquimod cream]. Actas Dermosifiliogr. 2010;101:551-2.
Chan MYL, Kennedy J, Oakley A. Erythema multiforme triggered by imiquimod 5% cream. Australas J Dermatol. 2017;58:e257-e258.
Peña-López S, Suárez-Magdalena O, Monteagudo B, Cabanillas M. Erythema Multiforme Caused by Treatment With Topical Imiquimod 5% in a Patient With Gorlin Syndrome. Actas Dermosifiliogr (Engl Ed). 2018; (3):277-278.
Maxfield L, Gaston D, Peck A, Hansen K. Topical Imiquimod and Subsequent Erythema Multiforme. J Am Osteopath Assoc. 2019.
Ballester I, Guijarro J, Silvestre JF, Niveiro M. Erythema multiforme induced by imiquimod 5% cream. Int J Dermatol. 2014;53:e347-8.
Yanes DA, Kaffenberger JA, Carr DR. Erythema multiforme as a reaction to imiquimod 5% cream. Dermatol Online J. 2017;23
Trčko K. Imiquimod-associated erythema multiforme. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29:47-49.
Leitner C. Topical imiquimod—Be aware of the unexpected. JAAD. 2016;74:AB223.
Tedman A, Malla U, Vasanthakumar L, Buzacott K, Banney L. Stevens-Johnson syndrome due to topical imiquimod 5%. Aust J Gen Pract. 2020;49:662-664.
Trave, I., Salvi, I., Micalizzi, C., Castelli, R., Parodi, A., & Cozzani, E. (2024). Stevens-Johnson induced by imiquimod 5% cream: a case report. Dermatology Reports. https://DOI.org/10.4081/dr.2024.9930
Newkirk RE, Fomin DA, Braden MM. Erythema Multiforme Versus Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Subtle Difference in Presentation, Major Difference in Management. Mil Med. 2020 Sep 18;185(9-10):e1847-e1850. DOI: 10.1093/milmed/usaa029. PMID: 32373930
Das A, Banerjee A, Tripathy K. Topical moxifloxacin-induced Stevens-Johnson syndrome. J Cataract Refract Surg. 2017 Jun;43(6):860-861. DOI: 10.1016/j.jcrs.2017.03.043. PMID: 28732631.
Shaw B, Madden M, Crespo A, Madruga M, Carlan SJ. A Rare Case of Severe Stevens-Johnson Syndrome Triggered by Topical Ofloxacin. Am J Case Rep. 2023 Nov 12;24:e941992. DOI: 10.12659/AJCR.941992. PMID: 37952083; PMCID: PMC10654684
Núñez Ortiz A, Trigo Salado C, de la Cruz Ramírez MD, Herrera Justiniano JM, Leo Carnerero E. Topical mesalazine as a cause of Stevens-Johnson syndrome. Rev Esp Enferm Dig. 2018 Nov;110(11):736-738. DOI: 10.17235/reed.2018.5429/2017. PMID: 29931986.
Dhavaleshwar A, Nayak V, Hande M, Pai R. Topical moxifloxacin-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. J Postgrad Med. 2019 Apr-Jun;65(2):125-126. DOI: 10.4103/jpgm.JPGM_535_18. PMID: 31036782.
Praz SM, De Torrente A, Zender H, Schmied E, Schleppy CA, Genné D. Toxic epidermal necrolysis after topical intranasal application of Mupirocin. Infect Control Hosp Epidemiol 2003; 24: 459–460
Sachs B, Fischer-Barth W, Erdmann S, Merk HF, Seebeck J. Anaphylaxis and toxic epidermal necrolysis or Stevens-Johnson syndrome after nonmucosal topical drug application: fact or fiction? Allergy. 2007 Aug;62(8):877-83. DOI: 10.1111/j.1398-9995.2007.01398.x. PMID: 17620064
Newman JM, Rindler JM, Bergfeld WF, Brydon JK. Stevens–Johnson syndrome associated with a topical nitrogen mustard therapy. J Am Acad Dermatol 1997; 36: 112–114
Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, Marzano A, Quaglino P, De Simone C, Parodi A, Barletta E, Fabbri P. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006;155:722-8.
Bubna AK. Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015 Jul-Aug;47(4):354-9. DOI: 10.4103/0253-7613.161249. PMID: 26288465; PMCID: PMC4527053.
Harrison LI, Skinner SL, Marbury TC, Owens ML, Kurup S, McKane S, Greene RJ. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res. 2004;296:6-11.
Kokuba H, Aurelian L, Burnett J. Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol. 1999 Nov;113(5):808-15. DOI: 10.1046/j.1523-1747.1999.00754.x. PMID: 10571738.
Giacomel J, Zalaudek I. Dermoscopy of superficial basal cell carcinoma. Dermatol Surg. 2005;31:1710-3.
Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28;57(9):895. DOI: 10.3390/medicina57090895. PMID: 34577817
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ilaria Salvi, Ilaria Trave, Riccardo Castelli, Aurora Parodi, Emanuele Cozzani

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.